<HashMap><database>biostudies-literature</database><scores/><additional><omics_type>Unknown</omics_type><volume>23(1)</volume><submitter>Tokai Y</submitter><pubmed_abstract>&lt;h4>Background&lt;/h4>The effect of Helicobacter pylori (H.pylori) eradication therapy on mixed-histological-type gastric cancer remains unclear. This study aimed to clarify the effect of H. pylori eradication therapy on mixed-histological-type early gastric cancer using endoscopic and histological findings.&lt;h4>Methods&lt;/h4>This single-center, retrospective study included patients with mixed-histological-type gastric cancer who underwent endoscopic submucosal dissection at the Cancer Institute Hospital. We compared detailed magnifying endoscopy with narrow-band imaging findings between eradicated and non-eradicated groups of patients with differentiated-type- and undifferentiated-type-predominant cancers. Subsequently, we performed histological evaluations of the non-cancerous epithelium covering differentiated-type components.&lt;h4>Results&lt;/h4>A total of 124 patients with mixed-type early gastric cancer were enrolled (eradicated group: 62 differentiated-type-predominant cancer patients and 8 undifferentiated-type-predominant cancer patients; non-eradication group: 40 differentiated-type-predominant cancer patients and 14 undifferentiated-type-predominant cancer patients). Regarding differentiated-type-predominant cancer, differentiated-type findings were detected in all patients in eradicated and non-eradicated groups. The difference in the detection rate of undifferentiated-type findings between both groups was not significant in differentiated-type-predominant cancer patients. In differentiated-type-predominant cancers, the percentage of non-cancerous epithelium covering differentiated-type components was higher in the eradicated group than in the non-eradicated group (median: 60% vs. 40%, p &lt; 0.001).&lt;h4>Conclusions&lt;/h4>Although the pathological findings of differentiated-type-predominant cancer were affected by H. pylori eradication, eradication did not affect the diagnosis of differentiated-type-predominant early gastric cancer using magnifying endoscopy with narrow-band imaging. ME-NBI is useful for the early detection of D-MIX EGCs and diagnosis of histological types during endoscopy, regardless of whether H. pylori eradication therapy has been administered.</pubmed_abstract><journal>BMC gastroenterology</journal><pagination>425</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC10694948</full_dataset_link><repository>biostudies-literature</repository><pubmed_title>Effect of Helicobacter pylori eradication evaluated using magnifying endoscopy with narrow-band imaging in mixed-type early gastric Cancer.</pubmed_title><pmcid>PMC10694948</pmcid><pubmed_authors>Yoshio T</pubmed_authors><pubmed_authors>Yamamoto N</pubmed_authors><pubmed_authors>Ishiyama A</pubmed_authors><pubmed_authors>Horiuchi Y</pubmed_authors><pubmed_authors>Tokai Y</pubmed_authors><pubmed_authors>Fujisaki J</pubmed_authors><pubmed_authors>Yoshimizu S</pubmed_authors><pubmed_authors>Namikawa K</pubmed_authors><pubmed_authors>Hirasawa T</pubmed_authors></additional><is_claimable>false</is_claimable><name>Effect of Helicobacter pylori eradication evaluated using magnifying endoscopy with narrow-band imaging in mixed-type early gastric Cancer.</name><description>&lt;h4>Background&lt;/h4>The effect of Helicobacter pylori (H.pylori) eradication therapy on mixed-histological-type gastric cancer remains unclear. This study aimed to clarify the effect of H. pylori eradication therapy on mixed-histological-type early gastric cancer using endoscopic and histological findings.&lt;h4>Methods&lt;/h4>This single-center, retrospective study included patients with mixed-histological-type gastric cancer who underwent endoscopic submucosal dissection at the Cancer Institute Hospital. We compared detailed magnifying endoscopy with narrow-band imaging findings between eradicated and non-eradicated groups of patients with differentiated-type- and undifferentiated-type-predominant cancers. Subsequently, we performed histological evaluations of the non-cancerous epithelium covering differentiated-type components.&lt;h4>Results&lt;/h4>A total of 124 patients with mixed-type early gastric cancer were enrolled (eradicated group: 62 differentiated-type-predominant cancer patients and 8 undifferentiated-type-predominant cancer patients; non-eradication group: 40 differentiated-type-predominant cancer patients and 14 undifferentiated-type-predominant cancer patients). Regarding differentiated-type-predominant cancer, differentiated-type findings were detected in all patients in eradicated and non-eradicated groups. The difference in the detection rate of undifferentiated-type findings between both groups was not significant in differentiated-type-predominant cancer patients. In differentiated-type-predominant cancers, the percentage of non-cancerous epithelium covering differentiated-type components was higher in the eradicated group than in the non-eradicated group (median: 60% vs. 40%, p &lt; 0.001).&lt;h4>Conclusions&lt;/h4>Although the pathological findings of differentiated-type-predominant cancer were affected by H. pylori eradication, eradication did not affect the diagnosis of differentiated-type-predominant early gastric cancer using magnifying endoscopy with narrow-band imaging. ME-NBI is useful for the early detection of D-MIX EGCs and diagnosis of histological types during endoscopy, regardless of whether H. pylori eradication therapy has been administered.</description><dates><release>2023-01-01T00:00:00Z</release><publication>2023 Dec</publication><modification>2025-04-26T20:43:26.452Z</modification><creation>2025-02-19T01:18:01.633Z</creation></dates><accession>S-EPMC10694948</accession><cross_references><pubmed>38049718</pubmed><doi>10.1186/s12876-023-03064-z</doi></cross_references></HashMap>